Clinical and prognostic analysis of 78 patients with human immuno-deficiency virus associated non-Hodgkin’s lymphoma in Chinese population

Abstract

BackgroundHuman Immuno-deficiency Virus (HIV) associated non-Hodgkin’s lymphoma (NHL) was a special group of disease, which manifests distinct clinical features and prognosis as compared with NHLs in patients without HIV. We performed this study to describe the clinical features of the disease and investigated the potential prognostic factors.MethodsHIV-infected patients who were newly diagnosed with NHL were enrolled in this study. The selection of anti-lymphoma treatment regimen was mainly dependent on the pathological subtypes of NHLs. Tumor response was reviewed and classified according to the International Workshop Criteria.ResultsA total of 78 patients were enrolled, among whom, 42 (53.8%) were with Diffuse large B cell Lymphoma (DLBCL), and 29 (37.2%) were with Burkitt lymphoma (BL). BL patients presented with higher risk features as compared with DLBCL in terms of numbers of extranodal diseases (P = 0.004) and poor Eastern cooperative oncology group (ECOG) score (P = 0.038). The estimated 2-year overall survival (OS) and progression free survival (PFS) rate was 74.3 ± 8.1%, 28.9 ± 11.0%, and 54.2 ± 8.1%, 19.2 ± 7.5% for DLBCL and BL, respectively. In multivariate analysis, international prognostic index (IPI) score was an independent prognostic factor for predicting both OS (OR = 2.172, 95% CI 1.579–2.987, P < 0.001) and PFS (OR = 1.838, 95% CI 1.406–2.402, P < 0.001).ConclusionsHIV associated NHLs represents a group of heterogeneous aggressive diseases with poor prognosis. IPI parameters were still effective in predicting the prognosis of HIV associated NHLs.Electronic supplementary materialThe online version of this article (doi:10.1186/s13027-017-0120-2) contains supplementary material, which is available to authorized users.

Clinical characteristics and outcomes for HIV-associated Diffuse Large B-cell Lymphoma in China: A retrospective single-center study

“…We analyzed the clinical features and survival outcomes of HIV-infected DLBCL in the setting of cART in our series. Consistent with other recent studies, HIV-infected patients with DLBCL presented with a poor performance status, a high frequency of B symptoms, elevated LDH, advanced Ann Arbor stage and high aaIPI score [5,6,9,17,20]. Moreover, bulky disease was frequent.…”

“…The HIV epidemic appears to have obvious regional distribution in China, occurring frequently in Sichuan province and Yunnan province [14,15]. So far, there are only few studies described the clinical features of Chinese AIDS patients with DLBCL [16,17]. Herein, we retrospectively analyzed the characteristics and outcomes of Chinese HIV-infected DLBCL patients in Yunnan Provincial Infectious Diseases Hospital/Yunnan AIDS Care Center.…”

DA-EPOCH-R is more effective and less toxic than modified CODOX-M/IVAC-R for treating Chinese HIV-infected patients with Burkitt lymphoma: an uncontrolled retrospective clinical trial

“…With the introduction of combination antiretroviral therapy (cART), the survival of patients with acquired immunode ciency syndrome (AIDS)-associated lymphoma has increased three-fold since the era of highly active antiretroviral therapy (HAART) [1]. However, human immuno-de ciency virus (HIV)-positive patients with Burkitt lymphoma (BL), continue to have a very poor prognosis [2][3][4][5][6][7][8][9]. BL cases are rare among the general population, but they comprised 10-37.2% of HIV-associated NHL cases in the era of HAART [9][10][11].…”

“…However, human immuno-de ciency virus (HIV)-positive patients with Burkitt lymphoma (BL), continue to have a very poor prognosis [2][3][4][5][6][7][8][9]. BL cases are rare among the general population, but they comprised 10-37.2% of HIV-associated NHL cases in the era of HAART [9][10][11]. HIV-positive patients with BL closely resemble the general BL population in terms of stage, marrow involvement (33-35%), central nervous system (CNS) involvement (17-19%) [12], and histology [13].…”

“…BL is an aggressive type of non-Hodgkin lymphoma (NHL) characterized by obligate MYC expression, which drives a nearly 100% growth phase fraction. The prognosis of BL is signi cantly worse compared with that of diffuse large B-cell lymphoma (DLBCL), according to limited data on Chinese HIVrelated NHL cases [8,9]. Improved immune function in the HAART era has led to a reevaluation of full-dose, high-intensity chemotherapy.…”